Home
»
Press Room
»
Enzyme Immunoassay Market To Reach $24.77Bn By 2033

Enzyme Immunoassay Market To Reach $24.77 Billion By 2033

September 2025 | Report Format: Electronic (PDF)

Enzyme Immunoassay Market Growth & Trends

The global enzyme immunoassay market size is expected to reach USD 24.77 billion by 2033, registering a CAGR of 3.68% from 2025 to 2033, according to a new report by Grand View Research, Inc. Increasing prevalence of chronic and infectious diseases, rising demand for point-of-care testing, and growing awareness and healthcare expenditure are expected to boost the market further. Moreover, the increasing number of joint ventures, product launches amongst market players and rising government investment is also expected to have a positive impact on market growth. For instance, in July 2023, Anbio Biotechnology Limited launched the AF-100S FIA Solution, a handheld solution for point-of-care immunodiagnostics. This analyzer can detect a broad spectrum of analyte enzymes and perform up to 240 tests per hour.

Rising government investment is expected to significantly support the market growth of enzyme immunoassay technologies. Government investments aid in the expansion of healthcare infrastructure, primarily in developing countries. This expansion helps in the wider adoption and integration of EIA technologies in clinical settings, enhancing the capacity for early disease detection, monitoring, and management. It also facilitates the establishment of national health programs that can use EIAs for large-scale screening and surveillance activities, such as infectious disease control and prevention programs. For instance, in March 2022, the UK government announced an investment of USD 347 million to enhance research and development and the production of novel devices and diagnostics.

The COVID-19 pandemic had a significant impact on the market. The pandemic caused disturbances in the supply chain and manufacturing processes of various healthcare products, including EIA kits and reagents. These disruptions were due to lockdown measures, labor shortages, and logistical challenges. However, the pandemic impacted the market by accelerating the development and adoption of EIA technologies for the detection of SARS-CoV-2 antibodies. This surge in demand was driven by the need for mass testing to identify infected individuals and understand the spread of the virus. Enzyme immunoassays, known for their specificity and sensitivity, became vital tools in the fight against the pandemic, used for diagnosing active infections and studies to assess the extent of virus spread within populations.

The development and optimization of EIAs require significant expertise in both the biological and engineering aspects of the technology. Ensuring high specificity and sensitivity can be challenging, especially for novel or rapidly mutating targets. Obtaining regulatory approval for new assays is a lengthy and expensive process. Regulatory standards can vary significantly between different regions, complicating the global distribution and use of these assays.

key Request a free sample copy or view report summary: Enzyme Immunoassay Market Report

Enzyme Immunoassay Market Report Highlights

The reagents and kits segment contributed the largest share of 67.75% in 2024. Reagents and kits designed for enzyme immunoassays have found applications across a wide range of fields, including clinical diagnostics, pharmaceutical analysis, and food safety testing.
Based on application, the infectious diseases testing segment held the largest market share in 2024. The high prevalence and incidence rates of infectious diseases globally drive the demand for effective and efficient diagnostic methods.
In terms of specimen, the blood specimen segment held the largest share in 2024. Blood tests are a standard and crucial diagnostic tool across various medical specialties. Given that blood circulates throughout the body, it can carry markers of disease from different organs, making it an ideal specimen for broad-spectrum disease screening and monitoring, including infections, chronic diseases, and hormonal imbalances.
The hospital segment dominated the global market, holding a 31.10% revenue share in 2024. Hospitals are the main medical facilities where a variety of illnesses are identified and managed.
North America enzyme immunoassay industry accounted for the largest market share of 38.99% in 2024, mainly attributed to the advanced healthcare infrastructure and robust biotechnology research sectors in the U.S. Continuous investments and developments in these areas have led to innovations in EIA technologies, making them more efficient and reliable.